Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
Siddharth Sukumaran(Johnson & Johnson (United States)), Saroja Ramanujan(Unknown), Bonnee Rubinfeld, Divya Samineni, Keyang Xu(Macau University of Science and Technology), Douglas D. Leipold(Genesys (United States)), Crystal Zhang, Kapil Gadkar(Sea Turtle Conservancy), Kedan Lin(University of Delaware), Marija Milojic-Blair, Bei Wang(Sun Yat-sen University), Montserrat Carrasco‐Triguero(Sangamo BioSciences (United States)), Paul J. Fielder(Institute for Human Reproduction), Ola M. Saad(Snap (United States))
Cited by 27
Related Papers
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997
The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors
|Oncogene|1999|670
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373